158 related articles for article (PubMed ID: 14737756)
1. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
Heitjan DF; Li H
Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
[TBL] [Abstract][Full Text] [Related]
2. Bayesian estimation of cost-effectiveness from censored data.
Heitjan DF; Kim CY; Li H
Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian model averaging approach for cost-effectiveness analyses.
Conigliani C; Tancredi A
Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
[TBL] [Abstract][Full Text] [Related]
4. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data.
Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG
Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202
[TBL] [Abstract][Full Text] [Related]
5. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
Kikuchi T; Gittins J
Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
[TBL] [Abstract][Full Text] [Related]
6. Large-sample Bayesian posterior distributions for probabilistic sensitivity analysis.
Hazen GB; Huang M
Med Decis Making; 2006; 26(5):512-34. PubMed ID: 16997928
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian approach to net health benefits: an illustration and application to modeling HIV prevention.
Johnson-Masotti AP; Laud PW; Hoffmann RG; Hayat MJ; Pinkerton SD
Med Decis Making; 2004; 24(6):634-53. PubMed ID: 15534344
[TBL] [Abstract][Full Text] [Related]
8. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
Negrín MA; Vázquez-Polo FJ
J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
[TBL] [Abstract][Full Text] [Related]
9. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
Spiegelhalter DJ; Best NG
Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
[TBL] [Abstract][Full Text] [Related]
10. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
Nixon RM; Wonderling D; Grieve RD
Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353
[TBL] [Abstract][Full Text] [Related]
11. Bayesian monitoring of clinical trials with failure-time endpoints.
Rosner GL
Biometrics; 2005 Mar; 61(1):239-45. PubMed ID: 15737099
[TBL] [Abstract][Full Text] [Related]
12. Bayesian cost-effectiveness analysis from clinical trial data.
O'Hagan A; Stevens JW; Montmartin J
Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
[TBL] [Abstract][Full Text] [Related]
13. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
14. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation.
Vanness DJ; Kim WR
Health Econ; 2002 Sep; 11(6):551-66. PubMed ID: 12203757
[TBL] [Abstract][Full Text] [Related]
15. Bayesian regression models for cost-effectiveness analysis.
Polo FJ; Negrín M; Badía X; Roset M
Eur J Health Econ; 2005 Mar; 6(1):45-52. PubMed ID: 15517461
[TBL] [Abstract][Full Text] [Related]
16. Bayesian interim analysis in clinical trials.
Zhang X; Cutter G
Contemp Clin Trials; 2008 Sep; 29(5):751-5. PubMed ID: 18589003
[TBL] [Abstract][Full Text] [Related]
17. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
Elbasha EH
Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
[TBL] [Abstract][Full Text] [Related]
18. The choice of sample size: a mixed Bayesian / frequentist approach.
Pezeshk H; Nematollahi N; Maroufy V; Gittins J
Stat Methods Med Res; 2009 Apr; 18(2):183-94. PubMed ID: 18445695
[TBL] [Abstract][Full Text] [Related]
19. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane.
Negrín MA; Vázquez-Polo FJ
Health Econ; 2006 Apr; 15(4):363-72. PubMed ID: 16259048
[TBL] [Abstract][Full Text] [Related]
20. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.
Hoch JS; Rockx MA; Krahn AD
BMC Health Serv Res; 2006 Jun; 6():68. PubMed ID: 16756680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
